ArticleClinical, cosmetic and investigational dermatology2026
Deciphering the Causal Links Among Metabolomics, Ageing Phenotypes, and Pathological Scars: A Two-Sample Mendelian Randomization Study.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertrophic scars (HS) and keloids represent pathological outcomes following cutaneous injury, characterized by complex pathogenesis and suboptimal therapeutic outcomes. The interplay between metabolomics and ageing may offer novel intervention targets for scar formation. Objective: This study aimed to systematically investigate the causal relationships between blood metabolites, ageing phenotypes (telomere length, epigenetic age), and HS/keloids through Two-sample Mendelian randomization (MR) and Two-step Mediation MR analysis. Methods: We integrated large-scale GWAS data from European populations, including 1400 blood metabolites (n=8299), telomere length (n=438,351), epigenetic age (n=41,000), HS (2068 cases/465,673 controls), and keloids (4086 cases/1,278,496 controls). Two-sample MR analysis was performed using inverse-variance weighted (IVW) and Wald ratio methods. Steiger's, Cochrane's Q, and MR-Egger tests were applied to exclude reverse causality, heterogeneity, and pleiotropy. Mediation effects of ageing phenotypes were quantified. Results: The study identified 30 metabolites significantly associated with HS and 49 with keloids. Among ageing phenotypes, telomere length showed positive correlations with both scar types, whereas PhenoAge exhibited negative correlations. Key metabolites such as Eugenol sulfate and Phenylacetylglutamate regulated scar formation through dual pathways involving telomere length and PhenoAge. Conclusion: This study elucidated the causal metabolite-ageing-scar network through genetic evidence, identifying multiple potential therapeutic targets, including Eugenol sulfate and Phenylacetylglutamate. These findings establish a robust foundation for developing targeted metabolic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.